Fig. 7: More durable expression of pDNA LNPs and extended transgene expression duration by co-delivery of anti-inflammatory siRNA.

a, b Whole-body bioluminescence imaging of female BALB/c mice (6–8 weeks) at different time points after i.v. administration of a single dosage of LNPs containing 25 μg of Luc pDNA per mouse or 5 μg of Luc mRNA per mouse for mRNA LNPs (n = 3, 21 mice in total). A mRNA LNP with the same composition as the ONPATTRO® was used as a control. c–e Whole-body bioluminescence imaging of female BALB/c mice (6–8 weeks) at different time points post-administration (25 μg Luc pDNA per mouse, 2.5 μg siRNA for each transcription factor per mouse (n = 3, 12 mice in total). f The levels of transcription factors of treated mice were determined by ELISA at 7 days post-administration with single dosage. (female BALB/c mice (6–8 weeks), n = 3, 15 mice in total) g FACScan was used to determine the infiltrating inflammatory monocytes (CD45⁺CD11b⁺ cells) in the liver after treatments. (n = 3) Data above are presented as mean±S.E.M. Data were analyzed using one-way ANOVA and Tukey’s multiple comparisons test (two-sided) for Fig. 7c, e, f and g. Statistical P-values: No significance: NS; ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, ^****P < 0.0001. Without specific indications, the label above each group indicates the statistical comparison with the PBS control group. Source data are provided as a Source Data file.